Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung : Predictive factors for completion of treatment.
Phase 4
- Conditions
- on Small Cell Lung Cancer (NSCLC)Non Small Cell Lung Cancer (NSCLC)Cancer - Lung - Non small cell
- Registration Number
- ACTRN12607000043437
- Lead Sponsor
- South Eastern Illawarra Area Health service
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Stage IIIA/B histologically proven NSCLC. ECOG Performance Status 0 or1. Weight loss < 10% compared to original (pre-diagnosis) weight. FeV1 (Forced Expiratory volume 1 second) > 1.0L. Adequate hematological and biochemical reserve.
Exclusion Criteria
Glomerular Filtration Rate (GFR) < 50ml/min (Cockroft-Gault formula). Prior chemotherapy or irradiation. Prior diagnosis of invasive cancer within the last 2 years. Symptomatic sensory or motor neuropathy. Contraindications to steroids. Pregnant or breastfeeding mothers. Intercurrent medical illnesses precluding combined modality therapy (except with clinician's authorisation).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method